$JNJ

$JNJ Johnson & Johnson: Phase 3 ICONIC-TOTAL Two-Year ICOTYDE Data Show High Complete Clearance Rates at Difficult Psoriasis Sites ? • At Week 112, 60…

$JNJ - Johnson & Johnson announces new ICOTYDE® (icotrokinra) data in difficult-to-treat plaque psoriasis with proven durability through 2-years, affi…

$JNJ - Johnson & Johnson presents new data reinforcing sustained disease control and improved daily function achieved with IMAAVY® (nipocalimab-aahu)…

$JNJ - Johnson & Johnson announces TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to show significant improvement in spinal pain and stif…

$JNJ J&J - FIVE-YEAR OVERALL SURVIVAL RATE 69.2%, MEDIAN PROGRESSION-FREE SURVIVAL 60.5 MONTHS…

$JNJ - Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered five-year treatment-free remissions in 50% of patients in early line relapse…

$JNJ - New model-based analysis further supports the potential of TECVAYLI® (teclistamab-cqyv) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fi…

$JNJ - RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE® (lazertinib) with prophylactic strategies shows low rates of treatment-re…

$JNJ - Johnson & Johnson spotlights new neuropsychiatry data across bipolar mania, depression and schizophrenia at Psych Congress 2026…

$JNJ - Johnson & Johnson to Participate in the Deutsche Bank 2026 Healthcare Summit…

$JNJ - Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results…